micro-community-banner
  • Saved
Myeloid TM6SF2 Deficiency Inhibits Atherosclerosis - PubMed

Myeloid TM6SF2 Deficiency Inhibits Atherosclerosis - PubMed

Source : https://pubmed.ncbi.nlm.nih.gov/36139452/

Genetic variants in transmembrane 6 superfamily member 2 ( TM6SF2 ), such as E167K, are associated with atherosclerotic cardiovascular disease (ASCVD). Chronic inflammation and lipid-laden macrophage foam cell formation are...



Conclusions: Myeloid TM6SF2 deficiency inhibits atherosclerosis development and is a potential therapeutic target for the treatment of atherogenesis.


  • Saved
Approach to risk stratification of atherosclerotic cardiovascular disease

Approach to risk stratification of atherosclerotic cardiovascular disease

Source : https://www.cfp.ca/content/68/9/654

Objective To outline the 2021 Canadian Cardiovascular Society (CCS) dyslipidemia guidelines and to present the current approaches to cardiovascular risk stratification, including the incorporation of biomarkers and imaging tests. Sources...


Conclusions: Biomarkers and imaging tests have the potential to improve ASCVD risk stratification by reclassifying any patient whose risk has been inaccurately estimated by traditional methods. Recently published guidelines by the CCS suggest the use of biomarkers and imaging in certain patient groups.




  • Saved
Racial disparity in flu vaccine uptake among Asian American Individuals: A National Health Interview Survey Study

Racial disparity in flu vaccine uptake among Asian American Individuals: A National Health Interview Survey Study

Source : https://www.sciencedirect.com/science/article/abs/pii/S0146280622002882?via=ihub

Available online 12 September 2022, 101391 Vaccination coverage rates across Asian American subpopulations with atherosclerotic cardiovascular disease (ASCVD) and diabetes mellitus is not well-studied. We used data from the National...


Relevance: Vaccination coverage rates across Asian American subpopulations with atherosclerotic cardiovascular disease (ASCVD) and diabetes mellitus is not well-studied. We used data from the National Health Interview Survey (NHIS) from 2006-2018 and included participants with a history of ASCVD or diabetes.


  • Saved
Nonproteolytic Intracellular Domain of MT1-MMP (Membrane-Type 1 Matrix Metalloproteinase) Coordinately Modulates Abdominal Aortic Aneurysm and Atherosclerosis to Mice - PubMed

Nonproteolytic Intracellular Domain of MT1-MMP (Membrane-Type 1 Matrix Metalloproteinase) Coordinately Modulates Abdominal Aortic Aneurysm and Atherosclerosis to Mice - PubMed

Source : https://pubmed.ncbi.nlm.nih.gov/36073351/

Our findings show that the cytoplasmic domain of MT1-MMP safeguards from AAA and atherosclerotic plaque development through a proteolysis-independent signaling mechanism associated with Netrin-1 expression. This unexpected function of MT1-MMP...


Conclusions: Our findings show that the cytoplasmic domain of MT1-MMP safeguards from AAA and atherosclerotic plaque development through a proteolysis-independent signaling mechanism associated with Netrin-1 expression. This unexpected function of MT1-MMP unveils a novel mechanism of synchronous onset of AAA and atherogenesis and highlights its...

  • Saved
Network Meta-Analysis of Randomized Trials Evaluating the Comparative Efficacy of Lipid-Lowering Therapies Added to Maximally Tolerated Statins for the Reduction of Low-Density Lipoprotein Cholesterol - PubMed

Network Meta-Analysis of Randomized Trials Evaluating the Comparative Efficacy of Lipid-Lowering Therapies Added to Maximally Tolerated Statins for the Reduction of Low-Density Lipoprotein Cholesterol - PubMed

Source : https://pubmed.ncbi.nlm.nih.gov/36073669/

doi: 10.1161/JAHA.122.025551. Online ahead of print. 1 Cicarrone Center for the Prevention of Cardiovascular Disease Johns Hopkins University School of Medicine Baltimore MD. 2 Amgen Ltd Cambridge UK. 3 Amgen...


Conclusions: Evolocumab, 140 mg Q2W/420 mg once a month, and alirocumab, 150 mg Q2W, were consistently the most efficacious nonstatin regimens when added to maximally tolerated statins to lower LDL‐C, non–high‐density lipoprotein cholesterol, and apolipoprotein B levels and facilitate attainment of guideline‐recommended...